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NC-ND license (http://creativecommoSummary Background: Recurrence of hepatocellular carcinoma (HCC) after surgery is
frequent, and is an important factor adversely influencing the long-term survival of patients.
This prospective study evaluated whether adjuvant chemotherapy with oral tegafur/uracil
(UFT) reduces the recurrence rate of HCC. In addition, expression of thymidylate synthase
(TS) and dihydropyrimidine dehydrogenase (DPD) were investigated in resected tumors and
nontumorous tissues, and the relationship between their expression and the effectiveness of
UFT was examined.
Methods: A total of 117 patients who underwent curative hepatic resection for HCC were
randomly allocated to UFT 400 mg/d (n Z 24, UFT group) or surgery alone (n Z 56, control
group). The primary endpoint was the recurrence-free survival rate, and the secondary
endpoint was the overall survival rate. Expression of the DPD and TS genes were quantified
with TaqMan reverse transcription-polymerase chain reaction assay using b-actin as an internal
standard. The cut-off value was set at the mean value of TS and DPD expression.
Results: Among the 61 patients in the UFT group, 37 patients (60.6%) discontinued UFTwithin 1
month. Recurrence-free survival (pZ 0.16) and overall survival (pZ 0.29) were similar in the
two groups. In the UFT group, recurrence-free survival did not differ significantly between
high-TS (TS > 3.6) and high-DPD (DPD > 8.9; n Z 10), and low-TS (TS  3.6) and low-DPD
(DPD  8.9; n Z 9) groups. However, there was a significant difference between the two
groups in overall survival (p Z 0.04).onflicts of interest to declare.
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150 M. Ishizuka et al.Conclusion: Peroral UFT administration fails to prolong the recurrence-free rates and overall
survival rates, in comparison with surgery alone. However, oral administration of UFT may
improve the survival of HCC patients when the levels of TS and DPD mRNA are low in the tumor
tissue.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Although the safety of hepatic resection for hepatocellular
carcinoma (HCC) has been improved,1,2 the cancer
frequently recurs after surgery, and this is an important
factor adversely influencing long-term survival.3,4 The
remaining liver is the predominant site of recurrence.
Various efforts to reduce the risk of recurrence after he-
patic resection have been attempted, including different
regimens of adjuvant chemotherapy and neoadjuvant
chemotherapy.5,6 However, their effectiveness for preven-
tion of HCC recurrence is controversial.
Uracil-tegafur (UFT, Taiho Pharmaceutical Co., Tokyo,
Japan), an oral fluorinated pyrimidine chemotherapeutic
agent, has been used for adjuvant chemotherapy against
several tumor types (particularly colorectal and lung can-
cer).7,8 Although this is effective in some HCC patients,
most patients do not receive the benefit from the agent.9,10
Therefore, prediction of the sensitivity of each patient with
HCC to this agent is important for avoiding unnecessary
administration.
Thymidylate synthase (TS) and dihydropyrimidine dehy-
drogenase (DPD) are key enzymes in the regulation of 5-
fluorouracil (5-FU) metabolism. TS is an essential enzyme
for DNA synthesis, and is inhibited by the 5-FU metabolite
5-fluoro-20-deoxyuridylate 50-monophosphate. Several
studies have demonstrated a correlation between high
levels of TS and resistance to 5-FU.11,12 However, DPD,
which is both an initial and rate-limiting enzyme in the
catabolism of 5-FU, has been reported to play an important
role in 5-FU pharmacokinetics; > 80% of administered 5-FU
is converted to the inactive metabolite 5-fluoro-5, 6-
dihydrouracil through a catabolic pathway.13 An associa-
tion between high DPD levels and 5-FU resistance has been
reported.14,15 Recently, basic and clinical researchers have
demonstrated a correlation between the antitumor effect
of 5-FU and the levels of TS mRNA or DPD mRNA in tumors
by using Taqman reverse-transcription polymerase chain
reaction (RT-PCR).16 However, there have been no reports
of correlations between the quantitative amounts of TS
mRNA and DPD mRNA and survival duration in patients with
HCC receiving radical surgery combined with adjuvant oral
UFT chemotherapy.
The aim of this prospective study was to evaluate
whether adjuvant chemotherapy with oral UFT reduces the
recurrence rate of HCC. In addition, the expression of TS
and DPD was investigated in resected tumors, and its
relationship with the effectiveness of UFT was examined.2. Methods
One hundred and seventeen patients with HCC who had un-
dergone initial curative hepatic resection at Dokkyo Medical
University Hospital, Tochigi, Japan between August 2002 and
February 2006 were enrolled in a prospective randomized
study of postoperative adjuvant chemotherapy. The inclu-
sive criteria were: (1) absence of residual or recurrent tu-
mors at 1 month after curative surgery; (2) patient age
15e75 years; (3) liver function Child-Pugh class A or B; and
(4) absence of severe renal or cardiac disease. All patients
were informed of the nature and risks of the study, and
written informed consent was obtained from all of them.
Patients were allocated randomly to either a UFT group or a
control group using the minimization method.17 UFT
(400 mg/d) was administered orally for at least 1 year in the
UFT group, the administration of UFT started at 1 month
after surgery. The control group received surgery alone. No
patient received radiation or chemotherapy before surgery
or other chemotherapy during the study period.
The primary end point was the recurrence-free survival
rate, and the secondary end point was overall survival rate.
The follow-up study protocol was uniform for all patients,
and included a serum a-fetoprotein assay and an ultraso-
nography performed every 4 weeks, dynamic computed
tomography performed every 3 months, and chest radio-
graph performed every 6 months for the 1st year, and the
intervals of these examinations were gradually increased
after the 1st year. When recurrence was confirmed using
appropriate imaging, adjuvant chemotherapy was stopped
and the disease was treated accordingly with treatment
modalities such as reoperation, transarterial chemo-
embolization, or systemic chemotherapy. If patients had
less than four recurrent HCCs, they underwent reoperation
on the basis of Makuuchi’s criteria. However, if patients had
more than three recurrent HCCs, they underwent trans-
arterial chemoembolization, radio-frequency ablation, or
systemic chemotherapy instead of reoperation.2.1. Measurement of TS and DPD activities
Tumor tissue and adjacent normal tissue were obtained
from surgically resected samples and stored at 80C until
assayed.
TS and DPD gene expression was quantified with RT-PCR
assay (Hoffman-La Roche, Inc., Nutley, NJ, USA) using b-
actin as an internal standard, and expressed as the TS: b-
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at the median value of TS or DPD expression.2.2. Statistical analysis
Data are expressed as mean  SD. The ManneWhitney U
test or Chi-square test was used where appropriate for
comparing clinical parameters between the two groups.
Recurrence-free and overall survival curves were obtained
using the KaplaneMeier method, and survival rates were
compared between the groups using the Wilcoxon test. For
all tests, differences at p < 0.05 were considered
significant.Figure 2 Recurrence-free and overall survival curves after
curative resection of HCC. Recurrence-free survival curves
after curative resection of HCC in the UFT group and control
group (p Z 0.16).3. Results
A total of 117 patients who underwent curative hepatic
resection for HCC were randomly allocated to UFT 400 mg/
d (n Z 61 UFT group) or surgery alone (n Z 56, control
group). Treatment with UFT was permanently discontinued
in 37 patients because of withdrawal of consent (n Z 14),
liver dysfunction (n Z 5), gastrointestinal symptoms
(n Z 5), ischemic heart disease (n Z 4), pleural effusion
(n Z 3), anemia (n Z 3), and eczema (n Z 3) within 1
month after the start of administration. There were a lot of
side effects due to administration of UFT in patients with
HCC. The remaining 24 patients were analyzed. No adverse
effects occurred in these patients, and the characteristics
of the two groups were similar (Figure 1).
Median follow-up was 2.8 years (range, 0.5e5.5 years).
Recurrence-free survival (p Z 0.16) and overall survival
(pZ 0.29) were similar in the two groups. The recurrence-
free survival rates at 1 year and 3 years were 87% and 27.5%
in the UFT group, and 58.5% and 25.4% in the control group,
respectively (Figure 2). The overall survival rate at 3 years
and 5 years were 89.3% and 64.3% in the UFT group, andFigure 1 Flow chart o75.9% and 62.2% in the control group, respectively
(Figure 3).
3.1. Levels of TS and DPD mRNA in tumors and
adjacent tissue
The relative gene expressions of TS and DPD in tumor tis-
sues were observed to be 2.16- and 3.34-fold higher
compared with adjacent control tissues.
Measurements of TS and DPD expression in the UFT group
were available for 21 samples, and the ranges were
0.03e17.8 and 0.51e32.1, respectively. Similarly, mea-
surement of TS and DPD expression in the control group
were available for 35 samples, and the ranges were
0.06e23.4 and 0.18e40.3, respectively.
The respective cut-off values of TS and DPD expression
in the UFT group were 3.6 and 8.91, and those in the control
group were 3.08 and 8.41 (difference not significant).f patient allocation.
Figure 3 Recurrence-free and overall survival curves after
curative resection of HCC. Overall survival curves after cura-
tive resection of HCC in the UFT Group and Control Group
(p Z 0.29).
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significantly between the high-TS and high-DPD (n Z 10).
and low-TS and low-DPD groups (nZ 9; Figure 4). However,
there was a significant difference between the two groups
in overall survival (p Z 0.04; Figure 5).Figure 4 Relationships between recurrences and, TS mRNA and D
The dotted lines indicate the median value of each mRNA level.
Figure 5 Overall survival curve in the UFT Group with low-TS a
(TS > 3.6, DPD > 8.9; p Z 0.04).4. Discussion
The response to conventional fluoropyrimidine derivatives
can be inadequate in patients with HCC. Because a poor
response is caused by the increased activity of the 5-FU-
metabolizing enzyme DPD in the tumor tissue, inhibition of
DPD could lead to prolongation of the active concentrations
of 5-FU. Fluoropyrimidine derivatives combined with a DPD
inhibitor are termed DPD inhibitory fluoropyrimidine. UFT
was the first such DPD inhibitory fluoropyrimidine to be
applied, and is now widely used.
Adjuvant oral chemotherapy with UFT has been shown to
be effective against HCC recurrence,9,10 but negative re-
sults of adjuvant chemotherapy in terms of overall survival
have also been reported.18 In the present study, we ex-
pected that adjuvant chemotherapy with UFT after hepatic
resection might effectively kill residual microscopic tumor
cells in the remnant liver and circulation. However, con-
trary to expectation, there were no significant differences
in the recurrence-free and overall survival rates between
the UFT group and control group. Although no adverse ef-
fects occurred in the UFT group, our data are similar to the
results of another prospective study by Hasegawa et al.18
Our study is the first to have examined the expression of
both TS and DPD in the same specimens of HCC to evaluatePD mRNA levels in 21 samples of HCC tissues in the UFT group.
nd low-DPD (TS  3.6, DPD  8.9), and high-TS and high-DPD
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vary among different types of cancer. In HCC, expression of
DPD mRNA and TS mRNA was generally higher than those of
other types of cancers (mean  SD valueZ 1.34  1.79 and
2.81  3.13, respectively).19 It has also been suggested that
the response to 5-FU varies depending on the type of can-
cer, and is related to the expression levels of 5-FU-related
enzymes. Theoretically, the lower activities of TS and DPD
in tumors produce the better response to 5-FU.20e22 In fact,
low TS patients who received hepatic artery infusion
chemotherapy had 4.1 times higher response for colorectal
liver metastases than those of high TS patients.23 Further-
more, in patients with neck and head cancer, complete
responders had a significantly lower DPD activity than those
of partial or no responders.24 Miyoshi et al8 have also re-
ported that adjuvant chemotherapy with UFT might
improve the survival of patients with nonsmall cell lung
cancer when TS levels in tumor tissues are low. Therefore,
although a previous study18 revealed that there was no
difference between the UFT group and the control group in
overall survival, the low-TS and low-DPD group would have
a higher overall survival rate than those of control group
when investigation of the TS and DPD expression was
performed.
Conversely, Mizutani et al25 have reported that higher TS
activity in primary-cultured RCC was predictive of higher
sensitivity to 5-FU. Similarly, higher TS expression was re-
ported to be significantly associated with longer survival in
patients with stage II colon cancer.26 One possible reason
for these conflicting results might be as follows. Although
excessively high expression of TS in tumor tissue would
reduce the sensitivity to 5-FU in highly proliferative cancer
such as HCC, moderately high expression of TS in a tumor
would sensitize other types of cancer to 5-FU. The present
study also revealed that the expression of TS mRNA was
higher than those of other types of cancers.19
Our results revealed no significant difference in overall
survival rates between the UFT group and control group.
However, low-TS and low-DPD patients group who were
treated with UFT had a significant better survival rate than
those of high-TS and high-DPD patients group who were also
treated with UFT (p Z 0.04). Therefore, TS and DPD ac-
tivity is considered to be an important determinant of the
response to fluoropyrimidine drugs, and may be an inde-
pendent predictor of outcome.
Because the results, which were demonstrated with
quantitative RT-PCR, showed the TS or DPD/b-actin mRNA
ratio, there might be a discrepancy between the mRNA
expression levels and TS/DPD enzyme activities. In addition,
it would be better to define TS/DPD cut-off values using
receiver operating characteristic curve analyses than those
of median TS/DPD expression levels. In fact, although there
was no significant difference between low-TS and low-DPD,
and high-TS and high-DPD patients groups in the recurrence
rate (Figure 4), there was a significant difference between
these two groups in overall survival (Figure 5). However, a
previous study demonstrated that DPD protein in the liver
cytosol correlated with the activity of enzyme.27 Therefore,
it would be acceptable to use TS/DPD mRNA levels as prog-
nostic markers of HCC patients receiving UFT adjuvant
therapy, instead for TS/DPD enzyme activities. In addition, a
possible explanation for this discrepancy betweenrecurrence-free and overall survival is based on a hypothesis
that there is a difference between carcinogenesis and tumor
progress in patients with HCC. Even if UFT treatment might
be effective for suppressing tumor progression in patients
with low-TS and low-DPD, there might be no relationship
between UFT treatment and HCC recurrence in the residual
liver after liver resection for HCC. In fact, both TS and DPD
expression levels were lower in the control tissues than those
in the tumor tissues.
In conclusion, adjuvant chemotherapy with UFT may not
be useful for HCC patients. However, when TS and DPD
activity is low in tumor tissue, oral administration of UFT
after surgery might improve survival. Because the results of
this study were based on a small number of patients,
further prospective randomized controlled studies with
larger numbers of cases will be required to verify our re-
sults. In addition, because there was a high withdraw rate
from the UFT group in the study, use of UFT should be
seriously considered in the following studies.
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